Cell Therapy of -Sarcoglycan Null Dystrophic Mice Through Intra-Arterial Delivery of Mesoangioblasts - Wikidata - awgldk - TriplyDB

Cell Therapy of -Sarcoglycan Null Dystrophic Mice Through Intra-Arterial Delivery of Mesoangioblasts

Cell Therapy of -Sarcoglycan Null Dystrophic Mice Through Intra-Arterial Delivery of Mesoangioblasts

http://www.wikidata.org/entity/Q29302095

about

Injectable polyethylene glycol-fibrinogen hydrogel adjuvant improves survival and differentiation of transplanted mesoangioblasts in acute and chronic skeletal-muscle degeneration.Molecular and cell-based therapies for muscle degenerations: a road under construction Skeletal muscle stem cells The emerging role of viral vectors as vehicles for DMD gene editing The Toll of Vascular Insufficiency: Implications for the Management of Peripheral Arterial Disease Increased Understanding of Stem Cell Behavior in Neurodegenerative and Neuromuscular Disorders by Use of Noninvasive Cell Imaging Role of Inflammation in Muscle Homeostasis and Myogenesis Stem cells for skeletal muscle regeneration: therapeutic potential and roadblocks Metabolic reprogramming as a novel regulator of skeletal muscle development and regeneration Perspectives of stem cell therapy in Duchenne muscular dystrophy Recent progress in satellite cell/myoblast engraftment -- relevance for therapy Laminin regulates PDGFRβ(+) cell stemness and muscle development.Nutraceuticals and Their Potential to Treat Duchenne Muscular Dystrophy: Separating the Credible from the Conjecture Inflammation induced loss of skeletal muscle Plasticity of spermatogonial stem cells Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade Cell death, clearance and immunity in the skeletal muscle Inflammation converts human mesoangioblasts into targets of alloreactive immune responses: implications for allogeneic cell therapy of DMD Combinations of Kinase Inhibitors Protecting Myoblasts against Hypoxia Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation miR669a and miR669q prevent skeletal muscle differentiation in postnatal cardiac progenitors Transplantated mesenchymal stem cells derived from embryonic stem cells promote muscle regeneration and accelerate functional recovery of injured skeletal muscle.Human satellite cells have regenerative capacity and are genetically manipulable.Systemic delivery of human microdystrophin to regenerating mouse dystrophic muscle by muscle progenitor cells Myoblast transplantation for inherited myopathies: a clinical approach.Magic-factor 1, a partial agonist of Met, induces muscle hypertrophy by protecting myogenic progenitors from apoptosis.Cooperation of Mtmr8 with PI3K regulates actin filament modeling and muscle development in zebrafish Immune regulatory neural stem/precursor cells protect from central nervous system autoimmunity by restraining dendritic cell function Skeletal muscle phenotypically converts and selectively inhibits metastatic cells in mice Repairing skeletal muscle: regenerative potential of skeletal muscle stem cells.Human skeletal muscle-derived CD133(+) cells form functional satellite cells after intramuscular transplantation in immunodeficient host mice Enhancement of myogenic and muscle repair capacities of human adipose-derived stem cells with forced expression of MyoD.Influence of immune responses in gene/stem cell therapies for muscular dystrophies.Intramuscular cell transplantation as a potential treatment of myopathies: clinical and preclinical relevant data.Human myogenic reserve cells are quiescent stem cells that contribute to muscle regeneration after intramuscular transplantation in immunodeficient mice "Mesenchymal" stem cells in human bone marrow (skeletal stem cells): a critical discussion of their nature, identity, and significance in incurable skeletal disease.Pharmacological Inhibition of PKCθ Counteracts Muscle Disease in a Mouse Model of Duchenne Muscular Dystrophy.Satellite cells and the muscle stem cell niche Gene and cell-mediated therapies for muscular dystrophy.Partial dysferlin reconstitution by adult murine mesoangioblasts is sufficient for full functional recovery in a murine model of dysferlinopathy.

P2860

Q22001191-8065F5E6-DA9E-45F6-8FA0-C22C91782546 Q24568176-F89DEEF3-41AA-4E92-9F4B-980C2DB3FB2A Q24801042-03C865D6-99E3-4450-803A-7C13942BAB58 Q26746647-1D504204-1D43-429D-991A-275E02899C7C Q26753079-2B504622-B723-43B1-846B-A27BB2D1447D Q26753150-B3F0DEBF-9557-4CC3-9970-C8322C3C24C8 Q26778322-FF1A0B39-EBB5-4EEA-9912-554611EA1521 Q26828390-217BBC5C-4515-4CD7-B44A-A2EE572F6EF2 Q27002421-D1DDD946-68C4-4F69-9F00-2050648497E7 Q27013613-06C7AD4A-69C5-42AF-A296-A0394D05D344 Q27014183-B6F354E2-2121-4434-A2AD-973D34C1723A Q27318580-90EABE39-B297-49B0-B6A9-8DAF4B9453B3 Q28072269-C6BFBA6E-0206-441E-B9F4-739999B3DC09 Q28083759-56621775-E574-4158-AA14-B8F2C5AC4AF2 Q28088720-A5420487-F21E-436B-9C23-AD6B5F6068E7 Q28288148-4E396D25-1277-49CF-9014-BBCFD37DBB9D Q28386837-4327BE4D-5976-475D-8A56-316DA56F8827 Q28389778-312935C9-F739-4EDC-819B-AE53DAB562A7 Q28547870-FFC7633A-3A23-4C56-8DDC-7949E1A3E91C Q28572865-B213F53A-D9A9-429C-AE6E-14E0FC2E82A9 Q28592363-2ED301C3-C17D-40CA-B342-CA349A76E2E7 Q30542052-A3D71A03-2862-476A-9EE5-B1E21D5A05BC Q30590830-45F092A2-851F-4264-BA50-A1E086136223 Q33198739-C4168FB0-82C2-47A6-8BE9-B9E6E7CFF1AF Q33209460-389158F6-5969-4456-8352-19028FB49467 Q33369840-3104B8BB-8CBF-412D-9E72-ABF7A0703C9A Q33422870-BC988776-B2EC-47B4-BF26-3D67B66E5D58 Q33471488-712FF2FE-85AB-4B0E-BF4B-FC2546ABEB91 Q33533313-BEA9563C-802F-4DFE-82D6-A9920F88954E Q33559684-D82D44DE-D060-4B0E-9F8C-6B2DCADB474B Q33562298-FF5910EE-D7CF-4995-87A4-FF4BF9A4817C Q33713683-67F34DD6-AC02-48E1-AF7A-C7B2A8955934 Q33736192-0BBB974F-A76E-41DC-8A73-322DB9FD1A6B Q33785188-68C1B314-639B-4A5B-8E12-23EAAE3C6EB7 Q33799526-0BB87192-9D47-4ED0-B82C-D10AEF2A877E Q33800712-FFF52432-66A3-470D-AF25-316C2ED6F03C Q33809437-6C973622-F1C8-4999-A31D-EE141FAA3502 Q33816665-9F3C51EA-53DB-415A-B02E-B6E14EB9D63F Q33831193-6E85E0A5-4AF0-4136-A95A-F0CF09A6BB56 Q33833512-F187682E-CD6C-4B90-9A24-D2AA72F2B2D4

P2860

Cell Therapy of -Sarcoglycan Null Dystrophic Mice Through Intra-Arterial Delivery of Mesoangioblasts

http://www.wikidata.org/entity/Q29302095

description

2003 nî lūn-bûn

@nan

2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Cell Therapy of -Sarcoglycan ...... al Delivery of Mesoangioblasts

@ast

Cell Therapy of -Sarcoglycan ...... al Delivery of Mesoangioblasts

@en

type

label

Cell Therapy of -Sarcoglycan ...... al Delivery of Mesoangioblasts

@ast

Cell Therapy of -Sarcoglycan ...... al Delivery of Mesoangioblasts

@en

prefLabel

Cell Therapy of -Sarcoglycan ...... al Delivery of Mesoangioblasts

@ast

Cell Therapy of -Sarcoglycan ...... al Delivery of Mesoangioblasts

@en

P1433

Q29302095-689A4A38-BAAB-4ED1-BEE2-3D321FB089CE

P1476

Q29302095-14ED25B1-576F-43E2-A7E8-F71BF9792D9E

P2093

Q29302095-2B00C760-97B0-453E-9B05-B858AEDDB81E

Q29302095-40C31AB4-FC86-47A3-ACEB-770951B695E6

Q29302095-468C65EC-B9B3-4C94-9EDE-29EADD68F13C

Q29302095-973CAA44-4F4C-4F80-8914-367E9E29C712

Q29302095-A544C602-B600-4FE4-8A85-44A7CCEB7712

Q29302095-A6165A15-882D-4B9D-98AE-F604544419EB

Q29302095-AE99A727-21B9-4EF8-9188-669700DB65C9

P304

Q29302095-980616B1-D9CB-4B9D-B8F5-A4DA51D08E84

P31

Q29302095-4CE4CFE2-2201-4E30-85A7-9B4D5CAACDD0

P3181

Q29302095-B4F5C540-5FA1-49CC-950A-70ED438B4AAE

P356

Q29302095-69C6C597-C0BA-4EC6-A70F-931827C61703

P407

Q29302095-7828D852-EF07-43D3-A64B-24F6FEE9FC96

P433

Q29302095-2E4D228C-05BA-4C38-9A44-BEC68D016114

P478

Q29302095-D59FE9A7-BB2A-46E5-B528-19CA2AEC829E

P50

Q29302095-629BB497-BEA3-448C-BAB6-98419D535AD0

Q29302095-716B8D04-AC20-405F-A034-86E496BA730A

Q29302095-8F59A1FD-72D3-4D11-AF6F-851BF6F1568C

Q29302095-A4BFCCBF-E873-4771-B397-ACCECAF91F55

Q29302095-F7370CB0-234E-49AC-A7FB-5868F9E22741

P577

Q29302095-A6F9CD90-7D80-40F5-A472-69FCAF4BCC8A

P5875

Q29302095-0C9DEDEF-41BB-4B31-ADE7-6A0A27FD5676

P698

Q29302095-1431B961-F095-45FD-A5E2-1CC618BA2E81

P3181

P356

SCIENCE.1082254

P1433

P1476

Cell therapy of alpha-sarcogly ...... al delivery of mesoangioblasts

@en

P2093

Anna Innocenzi

http://www.w3.org/2001/XMLSchema#string

Giulio Cossu

http://www.w3.org/2001/XMLSchema#string

M Antonietta Pellegrino

http://www.w3.org/2001/XMLSchema#string

M Gabriella Cusella De Angelis

http://www.w3.org/2001/XMLSchema#string

Rita Barresi

http://www.w3.org/2001/XMLSchema#string

Roberto Bottinelli

http://www.w3.org/2001/XMLSchema#string

Rossana Tonlorenzi

http://www.w3.org/2001/XMLSchema#string

P304

487-492

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1429369

http://www.w3.org/2001/XMLSchema#string

P356

10.1126/SCIENCE.1082254

http://www.w3.org/2001/XMLSchema#string

P407

P433

5632

http://www.w3.org/2001/XMLSchema#string

P478

301

http://www.w3.org/2001/XMLSchema#string

P50

Maurilio Sampaolesi

Giuseppe D'Antona

Kevin P Campbell

P577

2003-07-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10665861

http://www.w3.org/2001/XMLSchema#string

P698

12855815

http://www.w3.org/2001/XMLSchema#string